EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study
Q Zhou, CR Xu, Y Cheng, YP Liu, GY Chen, JW Cui… - Cancer cell, 2021 - cell.com
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung …
PBS3 and EPS1 complete salicylic acid biosynthesis from isochorismate in Arabidopsis
MP Torrens-Spence, A Bobokalonova, V Carballo… - Molecular plant, 2019 - cell.com
Salicylic acid (SA) is an important phytohormone mediating both local and systemic defense
responses in plants. Despite over half a century of research, how plants biosynthesize SA …
responses in plants. Despite over half a century of research, how plants biosynthesize SA …
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Q Zhong, X Xiao, Y Qiu, Z Xu, C Chen, B Chong… - MedComm, 2023 - Wiley Online Library
Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human …
MJ Ahn, JY Han, KH Lee, SW Kim, DW Kim… - The Lancet …, 2019 - thelancet.com
Background Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second …
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC …
MJ Hochmair, A Buder, S Schwab, OC Burghuber… - Targeted …, 2019 - Springer
Background Acquired epidermal growth factor receptor (EGFR) T790M mutation is the
primary resistance mechanism to first-generation EGFR tyrosine kinase inhibitors (TKIs) …
primary resistance mechanism to first-generation EGFR tyrosine kinase inhibitors (TKIs) …
A review of HER4 (ErbB4) kinase, its impact on cancer, and its inhibitors
MI El-Gamal, NH Mewafi, NE Abdelmotteleb… - Molecules, 2021 - mdpi.com
HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems
such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It …
such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It …
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer
B Nazha, JCH Yang, TK Owonikoko - Future Oncology, 2021 - Taylor & Francis
While randomized controlled trials (RCTs) are the gold standard for evidence-based
medicine, they do not always reflect real-world patient populations, limiting their …
medicine, they do not always reflect real-world patient populations, limiting their …